Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Semaglutide is a drug used for weight loss. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you may need to take them ...

We all know that Ozempic, a GLP-1 receptor agonist medication, also called semaglutide, causes weight loss. On average, high-dose semaglutides, like in Wegovy, cause people to lose somewhere ...

The side effects of Ozempic (semaglutide) can include abdominal (belly) pain, diarrhea, nausea, and vomiting, among other digestive-related problems. Ozempic is not a high-risk medication for most ...

As FDA shortages lift, patients and physicians explore new options for continued treatment with compounded GLP-1 medications.

Stephanie Anderson Witmer is a freelance journalist based in Pennsylvania. Her work has been published in other top magazines and digital publications, including Prevention, Good Housekeeping ...

This growing global health crisis calls for effective obesity treatments to reduce the burden on healthcare systems. Semaglutide, the weekly injectable drug better known by its brand names Ozempic and ...

weight change from baseline for NPM-139 (semaglutide) corrected to control (sham implant). Values are mean ± SE. In an ongoing study in healthy rats, a single administration of the semaglutide ...